Treatment Outcome Using Vivaer Stylus to Treat Nasal Airway Obstruction

Nasal Obstruction Clinical Trial

Official title:

A Prospective, Non-Randomized Study to Evaluate Treatment Outcome of Nasal Airway Obstruction Using the Aerin Medical Vivaer™ Stylus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03156270
• Other study ID #: TP423
• Status: Completed
• Phase: N/A
• Start date: September 19, 2017
• Est. completion date: August 6, 2019

Study information

• Verified date: October 2019
• Source: Aerin Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates subjective and objective measures of treatment outcome after using the Aerin Medical Vivaer™ Stylus to treat nasal obstruction

Description:

This is a non-significant risk, prospective, non-randomized study to evaluate subjective and objective measures of nasal obstruction both before and after treatment with the Vivaer Stylus. The Stylus is used to deliver radiofrequency (RF) energy to the nasal valve area to improve symptoms in those diagnosed with nasal airway obstruction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: August 6, 2019
• Est. primary completion date: July 12, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Complaints of nasal obstruction for at least 1 year

• Failed maximum medical therapy (4-6 weeks of steroids)

• Nasal Obstruction Symptom Evaluation (NOSE) score of = 60 at Baseline

• Nasal valve is a primary or significant contributor to the subject's nasal obstruction as determined by the study investigator (based on clinical presentation, physical examination, nasal endoscopy, etc.) and the subject has a positive response to any of the following temporary measures (based on patient history or during office exam):

1. Use of external nasal dilator strips (e.g., Breathe Right Strips)

2. Q-Tip test (manual intranasal lateralization)

3. Use of nasal stents

4. Cottle Maneuver (manual lateral retraction of the cheek)

Exclusion Criteria:

• Prior surgical treatment of the nasal valve

• Rhinoplasty, septoplasty, inferior turbinate reduction or other surgical nasal procedures within the past three (3) months

• Severe and/or chronic sinusitis, recurrent sinusitis, or allergies leading to nasal obstruction and currently requiring oral corticosteroid therapy

• Severe case of any of the following: septal deviation, turbinate hypertrophy, polyps, or ptotic nose tip believed to be the primary contributor to the subject's nasal obstruction symptoms and warranting surgical intervention

• Known or suspected allergies or contraindications to the anesthetic agents and/or antibiotic medications to be used during the study procedure session

• Known or suspected to be pregnant, or is lactating

• Other medical conditions which in the opinion of the investigator could predispose the subject to poor wound healing or increased surgical risk

Related Conditions & MeSH terms

• Airway Obstruction
• Nasal Obstruction

Intervention

Device:
• Vivaer Stylus
Stylus used to deliver low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area

Locations

Country	Name	City	State
United States	The Ohio State Eye and Ear Institute	Columbus	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Aerin Medical	Ohio State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in Peak Nasal Inspiratory Flow	Peak inspiratory flow measurements of nasal physical resistance	Baseline, 90 days
Primary	Change in NOSE Score	Mean change in Nasal Obstruction Symptom Evaluation (NOSE) score from baseline to 90 days post-study procedure. Improvement (90 day score - baseline score) is signified by a negative value.; The Nasal Obstruction Symptom Evaluation (NOSE) scale is a validated disease-specific health status outcomes instrument, used to assess severity of nasal obstruction symptoms. Score ranges from 0 to 100. Higher scores indicate increased symptoms/symptom severity.	Baseline, 90 days
Primary	Change in VAS of Nasal Obstruction	Change in visual-analog scale (VAS) of nasal obstruction severity as perceived by the subject from baseline to 90 days post-study procedure. Improvement (90-day score - baseline score) is signified by a negative value.; The visual-analog scale (VAS) of nasal obstruction is presented to the subject as a 10cm line anchored on each end by verbal descriptors: 0 = No Obstruction and 10 = Completely Obstructed. The subject is asked to place a vertical mark on the line to show the level of nasal obstruction they feel. The distance between 0 and the vertical mark made by the subject is measured and the results is expressed in centimeters. Higher scores indicate more severe obstruction.	Baseline, 90 days